Visit https://www.peervoice.com/YZK860 to view the entire programme with slides. After completing “Halting the Cascade of Chronic Kidney Disease: Can We Catch Patients Before They Fall?”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with chronic kidney disease (CKD), based on mechanisms of action; Analyse clinical evidence for safety and efficacy of oral therapy such as SGLT2 inhibitors in patients with CKD; and Describe the potential clinical implications of novel strategies on outcomes in CKD.

Visit https://www.peervoice.com/GWW860 to view the entire programme with slides. After completing “A Look at Emerging SMA Outcomes: Highlights of CureSMA 2020”, participants will be able to: Describe the pathogenesis of SMA in terms of potential therapeutic targets; Review current progress in terms of diagnosis and management; and Analyse clinical evidence for novel therapeutic targets in terms of outcomes and safety.

Visit https://www.peervoice.com/XBY860 to view the entire programme with slides. After completing “A Look at Emerging SMA Outcomes: Highlights of EAN 2020”, participants will be able to: Describe the pathogenesis of SMA in terms of potential therapeutic targets; Review current progress in terms of diagnosis and management; and Analyse clinical evidence for novel therapeutic targets in terms of outcomes and safety.

Visit https://www.peervoice.com/PSA860 to view the entire programme with slides. After completing “Deciphering the Role of MET Alterations in Advanced NSCLC: Unmet Needs”, participants will be able to: Describe the unmet treatment needs in patients with advanced non–small-cell lung cancer (NSCLC), and in particular MET exon 14 (METex14) skipping mutations; Summarise the impact of METex14 mutation on patient outcomes; and Discuss current and emerging treatment options for patients with METex14 mutations.

Visit https://www.peervoice.com/HHK860 to view the entire programme with slides. After completing “New Targets in IBD: Focus on IL-23”, participants will be able to: Explain the rationale for targeting IL-23 in inflammatory bowel disease (IBD); Evaluate the relative efficacy and safety of IL-23 inhibitors to date for patients with IBD; and Describe how these agents may fit into future treatment algorithms for IBD.

Are All Biologics the Same? Optimal Treatment Strategies for Patients With Inflammatory Bowel Disease

New Targets, New Hope in SMA: A 2020 Congress Coverage

Practice-Changing Perspectives in CMV: Managing the Burden in HSCT and SOT

Transforming the Treatment of Acute Hepatic Porphyria

Hidden in Plain Sight: Uncovering Truncal Acne